0001209191-20-006024.txt : 20200203
0001209191-20-006024.hdr.sgml : 20200203
20200203163203
ACCESSION NUMBER: 0001209191-20-006024
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20200123
FILED AS OF DATE: 20200203
DATE AS OF CHANGE: 20200203
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lawson Byron
CENTRAL INDEX KEY: 0001801387
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37369
FILM NUMBER: 20569080
MAIL ADDRESS:
STREET 1: C/O HTG MOLECULAR DIAGNOSTICS, INC.
STREET 2: 3430 E. GLOBAL LOOP
CITY: TUCSON
STATE: AZ
ZIP: 85706
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: HTG MOLECULAR DIAGNOSTICS, INC
CENTRAL INDEX KEY: 0001169987
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 860912294
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3430 E. GLOBAL LOOP
CITY: TUCSON
STATE: AZ
ZIP: 85706
BUSINESS PHONE: 877-289-2615
MAIL ADDRESS:
STREET 1: 3430 E. GLOBAL LOOP
CITY: TUCSON
STATE: AZ
ZIP: 85706
FORMER COMPANY:
FORMER CONFORMED NAME: HTG MOLECULAR DIAGNOSTICS INC
DATE OF NAME CHANGE: 20110523
FORMER COMPANY:
FORMER CONFORMED NAME: HIGH THROUGHPUT GENOMICS INC
DATE OF NAME CHANGE: 20020326
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2020-01-23
0
0001169987
HTG MOLECULAR DIAGNOSTICS, INC
HTGM
0001801387
Lawson Byron
C/O HTG MOLECULAR DIAGNOSTICS, INC.
3430 E. GLOBAL LOOP
TUCSON
AZ
85706
0
1
0
0
SVP/Chief Commercial Officer
Common Stock
43449
D
Stock Option (right to buy)
2.15
2022-10-02
Common Stock
931
D
Stock Option (right to buy)
2.15
2023-01-31
Common Stock
206
D
Stock Option (right to buy)
2.15
2023-08-05
Common Stock
1862
D
Stock Option (right to buy)
2.15
2024-03-19
Common Stock
5261
D
Stock Option (right to buy)
12.89
2024-12-28
Common Stock
1862
D
Stock Option (right to buy)
5.08
2025-11-24
Common Stock
10000
D
Stock Option (right to buy)
2.83
2026-05-25
Common Stock
5000
D
Stock Option (right to buy)
1.75
2027-01-31
Common Stock
10000
D
Stock Option (right to buy)
3.46
2027-05-31
Common Stock
5000
D
Stock Option (right to buy)
2.39
2027-07-25
Common Stock
7500
D
Stock Option (right to buy)
3.40
2028-08-16
Common Stock
30000
D
Stock Option (right to buy)
1.38
2029-08-06
Common Stock
65000
D
Stock Option (right to buy)
0.80
2029-09-12
Common Stock
35000
D
Stock Option (right to buy)
0.75
2030-01-07
Common Stock
70000
D
The shares subject to the stock option are fully vested.
The shares vest in a series of sixteen (16) successive equal quarterly installments on the last day of each calendar quarter, commencing with the last day of the calendar quarter first occuring after May 25, 2016.
The shares subject to the option will vest every three months in equal installments over four years beginning on August 31, 2017, such that the options is fully vested on May 31, 2021.
The shares vest in a series of sixteen (16) successive equal quarterly installments on the last day of each calendar quarter, commencing with the last day of the calendar quarter first occuring after August 16, 2018.
The shares will vest in equal monthly installments over a two-year period with the first vesting occurring on September 30, 2019, such that the stock option is fully vested on August 31, 2021.
The shares will vest in equal monthly installments over a two-year period with the first vesting occurring on January 31, 2020, such that the stock option is fully vested on December 31, 2021.
/s/ Shaun D. McMeans, Attorney-in-Fact
2020-02-03
EX-24.3_891378
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby constitutes and appoints
each of Shaun D. McMeans and John Lubniewski of HTG Molecular Diagnostics, Inc.
(the "Company"), signing individually, the undersigned's true and lawful
attorney-in-fact and agent to:
(1) execute for and on behalf of the undersigned, an officer, director or holder
of 10% of more of a registered class of securities of the Company, Forms 3, 4
and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934,
as amended (the "Exchange Act") and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to complete and execute such Form 3, 4 or 5,
complete and execute any amendment or amendments thereto, and timely file such
forms or amendments with the United States Securities and Exchange Commission
and any stock exchange or similar authority; and
(3) take any other action of any nature whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to such attorney-in-fact full power and authority
to do and perform any and every act and thing whatsoever requisite, necessary,
or proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as the undersigned might or could
do if personally present, with full power of substitution or revocation, hereby
ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorney-in-fact, in
serving in such capacity at the request of the undersigned, is not assuming, nor
is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the foregoing attorney-in-fact or (c) until such attorney-in-fact
shall no longer be employed by the Company.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 27 day of January, 2020.
/s/ Byron Lawson